학술논문
877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial.
Document Type
Article
Author
Source
Subject
*RENAL cell carcinoma
Language
ISSN
0923-7534